Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
NCT02368691
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
32
Enrollment
INDUSTRY
Sponsor class
Stopped
Lack of Efficacy
Conditions
Triple Negative Breast Cancer
Interventions
DRUG:
GTx-024
Sponsor
GTx